Depression Among Older Adults: A 20-Year Update on Five Common Myths and Misconceptions.
The American Journal of Geriatric Psychiatry. 2018; 26 (): 107-122
Lifetime and 12-month prevalence of Diagnostic and Statistical Manual of Mental Disorders, disorders among older African Americans: findings from the National Survey of American Life.
Am J Geriatr Psychiatry. 2007; 15: 652-659
Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981?2004.
Acta Psychiatrica Scandinavica. 2007; 116 (): 182-188
Prevalence of Mood, Anxiety, and Substance-Abuse Disorders for Older Americans in the National Comorbidity Survey-Replication The American.
Journal of Geriatric Psychiatry. 2009; 17 (): 769-781
Prevalence of mental disorders in the elderly: the Australian National Mental Health and Well-being.
Survey Acta Neuropsychiatrica. 2006; 18 (): 271-272
Depression in Long-Term Care.
J Am Med Dir Assoc. 2008; 9: 82-87
Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review.
Int Psychogeriatr. 2010; 22: 1025
Alexopoulos GS: Mechanisms and treatment of late-life depression Translational Psychiatry 2019; 9. Available at http://dx.doi.org/10.1038/s41398-019-0514-6.
Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms.
Neurosci Biobehav Rev. 2017; 74: 277-286
The relationship between depression and frailty syndrome: a systematic review.
Aging Ment Health. 2015; 19: 762-772
Depression in the elderly The.
Lancet. 2005; 365 (): 1961-1970
The vascular depression hypothesis: mechanisms linking vascular disease with depression.
Mol Psychiatry. 2013; 18: 963-974
The natural history of late-life depression: a 6-year prospective study in the community.
Arch Gen Psychiatry. 2002; 59: 605-611
The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disability.
J Am Geriatr Soc. 1999; 47: 647-652
Prognosis of depression in old age compared to middle age: a systematic review of comparative studies.
Am J Psychiatry. 2005; 162: 1588-1601
Predictors of recurrence in remitted late-life depression.
Depress Anxiety. 2018; 35: 658-667
Suicide in older adults: current perspectives.
Clin Interv Aging. 2018; 13: 691-699
Suicide rates in five-year age-bands after the age of 60 years: the international landscape†.
Aging & Mental Health. 2016; 20 (): 131-138
The Duration of the Suicidal Process.
The Journal of Clinical Psychiatry. 2009; 70 (): 19-24
An 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression American.
Journal of Psychiatry. 2003; 160 (): 1277-1285
Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness.
J Am Geriatr Soc. 2004; 52: 86-92
A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression.
Int Psychogeriatr. 1995; 7: 89-104
Efficacy of controlled-release paroxetine in the treatment of late-life depression.
J Clin Psychiatry. 2003; 64: 1065-1074
Depression in the Elderly.
N Engl J Med. 2014; 371: 1228-1236
Escitalopram in the acute treatment of depressed patients aged 60 years or older.
Am J Geriatr Psychiatry. 2008; 16: 14-20
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Am J Psychiatry. 2007; 164: 900-909
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Am J Geriatr Psychiatry. 2006; 14: 361-370
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.
J Clin Psychiatry. 2003; 64: 875-882
Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit.
Int J Geriatr Psychiatry. 2002; 17: 231-237
Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.
Pharmacol Res. 2017; 118: 19-32
Methylphenidate augmentation of citalopram in elderly depressed patients.
Am J Geriatr Psychiatry. 2001; 9: 298-303
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
Lancet. 2015; 386: 2404-2412
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report.
American Journal of Psychiatry. 2006; 163 (): 1905-1917
The Timing of Antidepressant Effects: A Comparison of Diverse.
Pharmacological and Somatic Treatments Pharmaceuticals. 2010; 3: 19-41
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Am J Psychiatry. 2013; 170: 1134-1142
Oral Ketamine for Depression: A Systematic Review.
J Clin Psychiatry. 2019; 80
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Biol Psychiatry. 2010; 67: 139-145
The use of ketamine as an antidepressant: a systematic review and meta-analysis Human Psychopharmacology.
Clinical and Experimental. 2015; 30: 152-163
Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
Am J Geriatr Psychiatry. 2017; 25: 1199-1209
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3.
Am J Geriatr Psychiatry. 2020; 28: 121-141
The Effectiveness of Repeated Intravenous Ketamine on Depressive Symptoms, Suicidal Ideation and Functional Disability in Adults with Major Depressive Disorder and Bipolar Disorder: Results from the Canadian Rapid Treatment Center of Excellence.
J Affect Disord. 2020;
When at first you don’t succeed: sequential strategies for antidepressant nonresponders.
J Clin Psychiatry. 1997; 58: 23-29
Diagnostic and Statistical Manual of Mental Disorders (DSM-5®).
American Psychiatric Pub,
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence Expert Opin Drug Saf. June 2020; : 1-10
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
Biol Psychiatry. 2003; 54: 573-583
Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Aust N Z J Psychiatry. 2017; 51: 55-64
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).
Journal of Traumatic Stress. 1998; 11 (): 125-136
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization.
Placebo-Controlled Study Biol Psychiatry. 2016; 80: 424-431
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
International Journal of Environmental Research and Public Health. 2018; 15 (): 771
A brief measure for assessing generalized anxiety disorder: the GAD-7.
Arch Intern Med. 2006; 166: 1092-1097
How to construct regression models for observational studies (and how NOT to do it!).
Canadian Journal of Anesthesia/Journal canadien d’anesthésie. 2017; 64 (): 461-470
Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation.
Am J Geriatr Psychiatry. 2016; 24: 918-922
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
J Affect Disord. 2018; 232: 310-315
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
J Affect Disord. 2018; 227: 11-16
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Pharmacological Reviews. 2018; 70 (): 621-660
EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION.
The American Journal of Geriatric Psychiatry. 2019; 27 (): S180-S181
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
J Affect Disord. 2020; 276: 576-584
Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept.
Trial J Palliat Med. 2013; 16: 958-965
Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.
Depress Anxiety. 2013; 30: 515-527
Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI).
Curr Opin Psychiatry. 2016; 29: 48-55